• Number of Subjects with treatment-related adverse events (AEs) [ Time Frame: Approximately 6 months ]
  Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit.
• Number of subjects with specific Manganese-related adverse events [ Time Frame: Approximately 6 months ]
  Manganese-related AEs were considered to be that start or worsen after administration Manganese administration，improve after withdrawal, and even occur again after re-administration.

• Preliminary efficacy evaluation [ Time Frame: Approximately 6 months ]
  Objective response rate (ORR) and disease control rate (DCR) will be evaluated by investigators per the RECIST V1.1.
• The q3w pharmacokinetic profile of Manganese [ Time Frame: Approximately 3 months ]
  PK parameters such as Maximum concentration (Cmax) are assessed.
• Number of participants with laboratory test abnormalities [ Time Frame: Approximately 3 months ]
  The laboratory tests of serum cytokines and chemokines will be performed on day 1 and 3 of each cycle, and the abnormality will be determined by the investigator.

• Solid Tumor
• Lymphoma

• Drug: Manganese Chloride
  Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
• Drug: Anti-PD-1 antibody
  Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
  Other Names:

  • Anti-PD-1 monoclonal antibody
  • PD-1 inhibitor
• Combination Product: Systemic therapy
  Whether and which should be given depends on the treatment regimen before enrollment.

• Active Comparator: Dose-Escalation, intranasally
  With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
  Interventions:

  • Drug: Manganese Chloride
  • Drug: Anti-PD-1 antibody
  • Combination Product: Systemic therapy
• Active Comparator: Dose-Escalation, inhalation
  With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
  Interventions:

  • Drug: Manganese Chloride
  • Drug: Anti-PD-1 antibody
  • Combination Product: Systemic therapy

Inclusion Criteria:

1. Subjects must have histologically proven unresectable/ metastatic solid tumors or lymphomas.
2. ≥ 18 years old.
3. Life expectancy of at least 6 months.
4. Eastern Cooperative Oncology Group performance status 0-2.
5. Subjects must have at least one measurable lesion ≥ 1 cm as defined by response criteria.
6. Subjects must have received at least two frontline therapies, except for patients initially diagnosed with local advanced or metastatic pancreatic cancer or cholangiocarcinoma.
7. Subjects must be off prior therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. Subjects with Anti-PD-1 antibody are eligible which must be resistance.
8. Adequate organ function.
9. Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.

Exclusion Criteria:

1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications.
2. Serious uncontrolled medical disorders or active infections, pulmonary infection especially.
3. T cell lymphomas or leukemia.
4. Prior organ allograft.
5. Women who are pregnant or breastfeeding.
6. Women with a positive pregnancy test on enrollment or prior to investigational product administration.
7. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.